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a b s t r a c t
Schwannomatosis is deﬁnedas anextremely rare tumors syndromecharacterizedby thepresenceofmul-
tiple schwannomas in the absence of typical signs of NF1 and NF2 syndromes. The genetic andmolecular
analysis performed on these tumors makes it possible to name schwannomatosis as distinct clinical and
genetic syndrome. The treatment in the case of symptomatic lesions is surgical removal; if the lesions are





lesions in patients with schwannomatosis, it remains imperative to perform serial brain and spinal cord
MRI studies during follow-up. The differential diagnosis is important including clinical and radiological
criteria plus molecular genetic analysis of tumor cells and lymphocyte DNA. We report a rare case of
spinal schwannomatosis in which genetic analysis performed on surgical samples showed two different




Schwannomas are encapsulated and slow growing benign
eripheral nerve tumors. They represent about one third of all
enign primary spinal tumors.1 Most schwannomas occur as iso-
ated lesions, but it is possible toﬁndmultiple localization involving
ne or more nerves.2,3 The presence of multiple schwannomas in
single patient is suggestive of a genetic predisposition to tumor
enesis and a possible associationwith syndromes such as neuroﬁ-
romatosis (NF). Among the different variants of NF only for NF1
nd NF2 National Institute of Health (NIH)4,5 have established the
uidelines for the diagnosis as described in the literature. NF1 is
he most common form, with an incidence at birth of 1/2500. The
ene for NF1 maps to the chromosome band 17q11.1. NF2, much
ess common (incidence at birth of approximately 1/33,000) and
s associated with signiﬁcant morbidity and mortality due to the
requent localization of the lesions in the brain and in the spinal
ord. The mutation in the NF2 gene maps to chromosome band
2q12.6 The most important ﬁnding for the diagnosis of NF2 is
he presence of bilateral schwannomas involving the eighth cra-
ial nerve, with an incidence of about 95% of patients. Individuals
ith NF2 also have an increased risk of developing single or multi-
le meningiomas and schwannomas of peripheral nerves. Lately, a
mall subset of patients with multiple schwannomas without any
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clinical signs and without any radiological evidence of vestibular
lesions or other characteristic features of NF2 has been identiﬁed.
The genetic and molecular analysis performed on the tumors of
these patients, revealed that it is possible to name schwannomato-
sis as a distinct clinical and genetic syndrome.7,8 Schwannomatosis
is deﬁned, therefore, as an extremely rare tumors syndrome char-
acterized by the presence of multiple schwannomas in the absence
of typical signs of NF1 and NF2 syndromes. Usually, patients
with schwannomatosis develop cranial, spinal or peripheral nerve
schwannomas but do not develop vestibular lesions (VS), typical of
NF2. Even the genetic features are different with respect to neu-
roﬁbromatosis, allowing one to classify the disease as a distinct
nosological entity. We report a rare case of spinal schwannomato-
sis inwhichgenetic analysisperformedonsurgical samples showed
two different mutations in the cells of the two lesions.
2. Case report
A 41-year-old man with a 10 years history of low back pain
presented with 2 years of worsening pain especially on awak-
ening, that improved partially during the day. An MRI without
contrast of the lumbosacral column showed the presence of two
small rounded areas of altered signal, slightly hyperintense on T2
Open access under CC BY-NC-ND license.and hypointense on T1 at T12 and L2–L3 levels (see Fig. 1). He was
referred because of these ﬁndings. A more detailed diagnosis was
performedwith contrast-enhancedMRI of thebrain and spinal cord
in its entirety. This examination conﬁrmed the presence of the two
areas of altered signal at T12 and L2–L3 levels with homogeneous
ense.





















Fig. 3. Intraoperative picture of the L2–L3 lesion after durotomy.ig. 1. Preoperative T1 and T2 weighted sagittal images: presence of two nodular
esions at T12 and L2–L3.
ontrast enhancement that looked like the neuroma (Figs. 1 and 2).
he study of the brain was negative. Because of the severity of
ow back pain that limited the daily activities of the patient it was
ecided to remove both the lesions surgically, by double laminec-
omy centered on tumors (Figs. 3 and 4). Removal of both lesions
as performed by microsurgical technique, with preservation of
he root. The entire procedure was performed under neurophys-
ological monitoring, in particular electromyography. Histological
xamination conﬁrmed the previous diagnosis of schwannoma, for
oth lesions. A genetic study was performed that showed two dif-
erent mutations for the two lesions: in particular a mutation in
xon 4 in the NF2 locus with loss of heterozygosity for the gene
F2CA3 for the lesion at T12 level, and a mutation at nucleotide
41 in exon 4 of the NF2 locus, with loss of heterozygosity for the
ene NF2CA3 for the lesion at L2–L3 level. A contrast-enhanced
RI control performed 3 months after surgery, showed the com-
lete removal of the lesions without any sign of recurrence (Fig. 5).
follow-upwith spinal and brainMRI every year has beenplanned.
Fig. 4. Intraoperative picture of T12 lesion after durotomy.
Fig. 2. Preoperative T1 with Gd-DTPA administration axial images: omogeneous enhancing of the lesions.








































lig. 5. Postoperative MRI with Gd-DTPA administration: complete removal of the
esions.
. Discussion
An important aspect for the classiﬁcation of schwannomatosis is
he differential diagnosis with NF. Schwannomatosis is a syndrome
hich can be deﬁned as characterized bymultiple schwannomas in
he absence of VS, having no characteristic of NF1 or NF2, having no
amiliarity and, having no constitutionalmutations of speciﬁc gene,
s like 17q11.1 inNF1 and22q12 inNF2.9 TheNF2 is caused by a “de
ovo”mutation at 22q12 inmore than 50% of patients. It is a tumor
uppressor gene with a molecular weight of 110kb, it consists of
6 consecutive exons and alternatively spliced exon. The protein
ncodedbyNF2gene is calledMerlin. TheMerlinhasa similar struc-
ure to the family of proteins that link cell surface glycoproteins to
ctin cytoskeleton. Schwannomatosis was ﬁrst described in 1973
s neuroﬁbromatosis type 3.10 The characteristic of this syndrome
as the presence ofmultiple skin and spinal’s schwannomas in the
bsence of vestibular involvement or other relevant features of NF1
ndNF2. Over time, several authors have reported cases of patients
ithmultiple schwannomaswithout vestibular lesions, suggesting
he existence of a distinct syndrome from the NF.
At this time there are no NIH diagnostic criteria for schwanno-
atosis. Jacobi et al.7 have proposed clinical criteria for diagnosis
f schwannomatosis: the presence of two ormore schwannomas in
he absenceof radiological evidenceof vestibular lesions inpatients
lder than 18 years, is deﬁnitely indicative of schwannomatosis.
ichael et al.4 have proposed an integration of these diagnostic
riteria, indicating the MRI exam as a fundamental instrument to
xclude the presence of vestibular schwannomas and,more impor-
ant is the absence of constitutional NF2mutations. The ﬁrst major
hallenge to the diagnosis of schwannomatosis is the presence of
wo or more non-intradermal schwannomas in patients older than
0 years, in the absence of vestibular lesions shown on the brain
RI with contrast enhancement and in the absence constitutional
F2mutations.11 A second important aspect is thepresenceof ﬁrst-
egree relative(s)with a conﬁrmeddiagnosis of schwannomastosis
n a patient with multiple schwannomas; these aspects have to be
hown in the absenceof vestibular lesions resulting onMRI imaging
nd genetic analysis. In the case of presence of ﬁrst-degree relative
here is no any limit of age for the diagnosis.
Several authors have studied the schwannomatosis molecular
enetics. Jacobi and MacCollins12 analyzed alterations in the NF2
ocus in patients with schwannomatosis revealing in the tumorrgery Case Reports 2 (2011) 36–39
cell, a typical truncating mutations at NF2 gene, with loss of het-
erozygosity of chromosome 22. In patients with NF2, no mutation
at NF2 locus was found in non-pathological tissues. In our case,
genetic analysis has included the study of the DNA of lymphocytes
taken from the patient’s peripheral blood and the study of the DNA
of cancer cells. There was a noticeable absence of constitutional
mutations in lymphocyte DNA, whereas in the DNA of tumor cells
were observed two distinct mutations, each one belonging to the
cell population of a schwannoma. In particular, the T12 lesion had
a mutation in exon 4 of the NF2 locus with loss of heterozygos-
ity of the NF2CA3 gene, whereas the lesion at L2–L3 level had a
mutation at nucleotide 441 in exon 4 of the NF2 locus, with loss
of heterozygosity of the NF2CA3 gene. In our case the absence of
speciﬁc signs of NF1 or NF2mutations associated with the absence
of constitutional mutation of lymphocytes DNA, characterize the
schwannomatosis as a syndrome, distinct from neuroﬁbromatosis.
Clearly, the treatment in case of symptomatic lesions is surgical
removal13 performed by laminotomy or laminectomy centered on
the lesion, followed by longitudinal durotomy and removal of the
lesion with preservation of the root as soon as possible. The use
of neurophysiological monitoring is extremely useful for the sur-
gical procedure because it prevents any neurological damage. In
the case of asymptomatic lesions it is important to perform serial
MRI. Moreover, given the high incidence of developing additional
lesions in patientswith schwannomatosis, it remains imperative to
perform serial MRI studies during follow-up.
4. Conclusion
Schwannomatosis ﬁts as a different syndrome from neuroﬁbro-
matosis. Thedifferential diagnosis includes clinical and radiological
criteria plus molecular genetic analysis of tumor cells and lym-
phocyte DNA. The treatment consists in surgical removal of
symptomatic lesionswith preservation of the root as early as possi-
ble. Serial MRIs to keep under control additional lesions frequently
seen in these patients is mandatory.





Written informed consent was obtained from the patient for
publication of this case report and accompanying images.
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